Valuation: Clene Inc.

Market Cap 56.15M 50.36M 46.02M 42.01M 79.15M 5.28B 81.65M 555M 221M 2.82B 211M 206M 8.89B P/E 2026 *
-1.62x
P/E 2027 * -2.31x
Enterprise Value 51.55M 46.23M 42.25M 38.57M 72.67M 4.85B 74.96M 509M 203M 2.59B 193M 189M 8.16B EV / Sales 2026 *
206x
EV / Sales 2027 * 2x
Free-Float
83.67%
Yield 2026 *
-
Yield 2027 * -
1 day-0.50%
1 week+3.13%
Current month+3.13%
1 month+1.80%
3 months-25.19%
6 months-45.74%
Current year-32.71%
1 week 3.63
Extreme 3.63
4.28
1 month 3.02
Extreme 3.0152
4.28
Current year 3.02
Extreme 3.0152
8.67
1 year 3.02
Extreme 3.0152
10.84
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
122.4
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
16/9/26 Free

Chief Executive Officer

15,244 0.1186%
16/9/26 Free

Chairman

434,451 3.3813%
16/9/26 Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-0.50%+3.13%-59.63%-52.52% 56.15M
-4.83%+3.51%+55.00%+62.02% 66.7B
+3.60%+7.83%+13.45%+83.58% 56.88B
+0.54%+2.96%+24.98%+96.76% 56.53B
+5.09%+9.89%+27.19%+103.27% 46.49B
+2.62%+1.68%+29.16%+36.08% 44.8B
+8.24%+0.51%+215.16%+807.84% 41.59B
-1.86%+10.13%+28.14%+53.61% 35.35B
+3.08%-1.38%+94.45%+66.15% 33.29B
+5.19%+1.62%-39.69%+381.71% 25.1B
Average +2.12%+2.70%+38.82%+163.85% 40.68B
Weighted average by Cap. +1.92%+3.07%+50.40%+167.29%

Financials

2026 *2027 *
Net sales 251K 225K 205K 188K 353K 23.56M 364K 2.48M 987K 12.57M 941K 920K 39.68M 29.03M 26.04M 23.8M 21.72M 40.93M 2.73B 42.22M 287M 114M 1.46B 109M 107M 4.6B
Net income -32.68M -29.31M -26.79M -24.46M -46.08M -3.07B -47.53M -323M -129M -1.64B -123M -120M -5.18B -31.29M -28.06M -25.65M -23.41M -44.11M -2.94B -45.5M -309M -123M -1.57B -117M -115M -4.95B
Net Debt -4.6M -4.13M -3.77M -3.44M -6.48M -432M -6.69M -45.45M -18.12M -231M -17.27M -16.9M -728M 1.8M 1.61M 1.48M 1.35M 2.54M 169M 2.62M 17.78M 7.09M 90.28M 6.76M 6.61M 285M
Projected Income Statement - Annual - Clene Inc.
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
06/11/26 US$3.950 -0.50% 60,759
05/11/26 US$3.970 -3.17% 116,946
04/11/26 US$4.100 +8.75% 115,847
03/11/26 US$3.770 +4.43% 44,337
02/11/26 US$3.610 -5.74% 54,014
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Clene Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.950USD
Average target price
32.20USD
Spread / Average Target
+715.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Clene Inc.
  1. Stock Market
  2. Stocks
  3. CLNN Stock